share_log

POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

POS AM：修改注册声明表
美股SEC公告 ·  07/30 16:11

Moomoo AI 已提取核心信息

eFFECTOR Therapeutics, Inc., a biopharmaceutical company based in Delaware, has filed a post-effective amendment with the Securities and Exchange Commission (SEC) on July 30, 2024, to deregister all unsold securities previously registered under two Registration Statements. The affected Registration Statements are No. 333-267221, filed on September 1, 2022, and No. 333-272738, filed on June 16, 2023. This move is in accordance with the company's previous undertakings to remove from registration any securities that remain unsold at the termination of the offering. The company, which is categorized as a non-accelerated filer, a smaller reporting company, and an emerging growth company, has taken this step to withdraw any and all securities that were registered but remain unsold as of the date of the amendment. The CEO of eFFECTOR Therapeutics, Craig Jalbert, has signed the amendment, indicating the company's belief that it meets all requirements for filing on Form S-3.
eFFECTOR Therapeutics, Inc., a biopharmaceutical company based in Delaware, has filed a post-effective amendment with the Securities and Exchange Commission (SEC) on July 30, 2024, to deregister all unsold securities previously registered under two Registration Statements. The affected Registration Statements are No. 333-267221, filed on September 1, 2022, and No. 333-272738, filed on June 16, 2023. This move is in accordance with the company's previous undertakings to remove from registration any securities that remain unsold at the termination of the offering. The company, which is categorized as a non-accelerated filer, a smaller reporting company, and an emerging growth company, has taken this step to withdraw any and all securities that were registered but remain unsold as of the date of the amendment. The CEO of eFFECTOR Therapeutics, Craig Jalbert, has signed the amendment, indicating the company's belief that it meets all requirements for filing on Form S-3.
eFFECTOR Therapeutics, Inc.是一家总部位于特拉华州的生物制药公司，在2024年7月30日向证券交易委员会（SEC）提交了一份有效后修正案，注销了早先根据两个注册声明之下注册但未售出的所有证券。受影响的注册声明分别为于2022年9月1日提交的333-267221号注册声明和于2023年6月16日提交的333-272738号注册声明。这一举动符合公司早先承诺在发行结束后注销任何未售出证券的要求。作为一个非加速发行人，较小规模的报告公司和新兴增长型企业，该公司采取了这一步骤，注销所有在修正案提交日期之前尚未售出的证券。eFFECTOR Therapeutics的首席执行官Craig Jalbert签署了修正案，表示该公司相信自己符合提交S-3表格的所有要求。
eFFECTOR Therapeutics, Inc.是一家总部位于特拉华州的生物制药公司，在2024年7月30日向证券交易委员会（SEC）提交了一份有效后修正案，注销了早先根据两个注册声明之下注册但未售出的所有证券。受影响的注册声明分别为于2022年9月1日提交的333-267221号注册声明和于2023年6月16日提交的333-272738号注册声明。这一举动符合公司早先承诺在发行结束后注销任何未售出证券的要求。作为一个非加速发行人，较小规模的报告公司和新兴增长型企业，该公司采取了这一步骤，注销所有在修正案提交日期之前尚未售出的证券。eFFECTOR Therapeutics的首席执行官Craig Jalbert签署了修正案，表示该公司相信自己符合提交S-3表格的所有要求。
有用
没用

该公告为独立文件：

独立文件1

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间